Enhanced oral bioavailability of Tanshinone IIA using lipid nanocapsules: Formulation, in-vitro appraisal and pharmacokinetics

[Display omitted] Tanshinone IIA (TSIIA) is a promising phytomedicine that has been extensively studied due to its numerous biological activities, especially as an anticancer drug. However, it suffers from poor oral bioavailability owing to low aqueous solubility, poor permeability and exposure to f...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2020-08, Vol.586, p.119598, Article 119598
Main Authors: Ashour, Asmaa A., Ramadan, Alyaa A., Abdelmonsif, Doaa A., El-Kamel, Amal H.
Format: Article
Language:English
Subjects:
Lipid nanocapsules
Oral bioavailability
Pharmacokinetics
Tanshinone IIA
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Tanshinone IIA (TSIIA) is a promising phytomedicine that has been extensively studied due to its numerous biological activities, especially as an anticancer drug. However, it suffers from poor oral bioavailability owing to low aqueous solubility, poor permeability and exposure to first-pass metabolism. This study endeavored to improve TSIIA oral bioavailability by encapsulation into lipid nanocapsules (LNCs) for the first time. A previously reported phase-inversion method was used to prepare Tanshinone II A loaded LNCs (TSIIA-LNCs) with slight modifications based on a constructed phase diagram. They were then in-vitro characterized and their oral pharmacokinetics were studied in rats. TSIIA-LNCs showed excellent colloidal properties (size; 70 nm, PDI 
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2020.119598